Skip to main content

Table 2 Clinical characteristics of patients with BM.

From: Breast cancer subtypes and survival in patients with brain metastases

 

No. (%)

p Value*

 

Total (n = 126)

Luminal A (n = 23)

Luminal B (n = 19)

HER2+/ER- (n = 37)

Triple-negative (n = 47)

 

Age, mean (range), y

47 (22–70)

46 (34–65)

48 (29–70)

48 (28–69)

47 (22–69)

0.773

Age at BM

      

≤ 45 years

59 (46.8)

13 (56.5)

8 (42.1)

16 (43.2)

22 (46.8)

0.746

> 45 years

67 (53.2)

10 (43.5)

11 (57.9)

21 (56.8)

25 (53.2)

 

AJCC stage:

     

0.812

I

20 (15.9)

3 (13.0)

1 (5.3)

6 (16.2)

10 (21.3)

 

II

34 (27.0)

6 (26.1)

7 (36.8)

8 (21.6)

13 (27.7)

 

III

41 (32.5)

7 (30.4)

6 (31.6)

14 (37.8)

14 (29.8)

 

IV

22 (17.5)

4 (17.4)

5 (26.3)

7 (18.9)

6 (12.8)

 

Unknown

9 (7.1)

3 (13.0)

0 (0.0)

2 (5.4)

4 (8.5)

 

Histology:

     

0.863

IDC

115 (91.3)

20 (87.0)

18 (94.7)

33 (89.0)

44 (93.6)

 

ILC

6 (4.8)

1 (4.3)

1 (5.3)

2 (5.4)

2 (4.3)

 

Mucinous

1 (0.8)

1 (4.3)

0 (0.0)

0 (0.0)

0 (0.0)

 

Metaplatic

4 (3.2)

1 (4.3)

0 (0.0)

2(5.4)

1 (2.1)

 

Disease-free interval, median (IQR), months

19.0 (25.0)

31.8(35.0)

26.9 (36.9)

17.5 (20.0)

17.0 (20.7)

0.1075

Interval from recurrence to BM, median (IQR), months

11.5 (15.2)

17.5 (36.0)

12.2 (17.0)

11.2 (14.3)

11.1 (14.5)

0.1473

Clinical features of BM:

     

0.053

Multiple

102 (81.0)

15 (65.2)

18 (94.7)

33 (89.2)

36 (76.6)

 

Single

11 (8.7)

2 (8.7)

1 (5.3)

1 (2.7)

7 (14.9)

 

LMD

13 (10.3)

6 (26.1)

0 (0.0)

3 (8.1)

4 (8.5)

 

Number of disease sites:

     

0.834

< 3

42 (33.3)

9 (39.1)

5 (26.3)

13 (35.1)

15 (31.9)

 

≥ 3

84 (67.7)

14 (60.9)

14 (73.7)

24 (64.9)

32 (68.1)

 

Extracranical metastatic site:

      

   Bone

80 (63.5)

18 (78.3)

16 (84.2)

24 (64.9)

22 (46.8)

0.010

   Lung/pleura

92 (73.0)

15 (65.2)

15 (78.9)

26 (70.3)

36 (76.6)

0.683

   Liver

52 (41.3)

10 (43.5)

13 (68.4)

14 (37.8)

15 (31.9)

0.053

   Skin/soft tissue/LN

94 (74.6)

15 (65.2)

12 (63.2)

30 (81.1)

37 (78.7)

0.122

  1. Abbreviations: AJCC, American Joint Committee on Cancer; BM, brain metastases; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IQR, interquartile range; LMD; leptomeningeal disease; LN, lymph node.
  2. *Comparing four groups (luminal A, luminal B, HER2+, triple-negative) using analysis of variances to test for differences in means, Kruskall-Wallis test for difference in medians, and chi-square or Fisher's exact test for the remaining characteristics.